| Detailed information |
|---|
| CancerLivER ID | 2108 |
| Biomarker | ABCC3 |
| Biomarker Name/Symbol (given in Publication) | ABCC3 |
| Biomolecule | Protein |
| Subject | Rat and Human |
| Degree of Validity | ABCC3 as a potential biomarker that is overexpressed in preneoplastic lesions and tumors and secreted into the plasma during the HCC development; But not validated on Human patients cohorts |
| Experimental Condition | Normal vs HCC |
| Cancer type | Hepatocellular carcinoma |
| Regulation | overexpressed in hepatocellular carcinoma |
| Level of significance | p < 0.01 |
| Source | Tissue |
| PMID | 26337276 |
| Type of Biomarker | Potential Diagnostic * |
| Pathway | Apoptotic pathway |
| Cohort | Tissue samples of 40 rats, divided in ten groups, nine of the groups treated according to the hepatocarcinogenesis model and a group not treated; Human HepG2 and Huh7 hepatocellular carcinoma cell lines |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Rat liver cancer, rat hepatocarcinogenesis model |
| Year of Publication | 2016 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |